



Author Acknowledgments

Editors

Linda McBride, RPh, RAC-US
Partner
IAA Consulting LLC

Siegfried Schmitt, PhD
Vice President Technical
Parexel

Authors

Kholoud M. Abdelfattah, MSc, CSRT-HMS
Regulator-Clinical Assessor
Egyptian Drug Authority

Sharry Arora, MPharm, MTOPRA, RAC-Drugs
Regulatory Affairs Consultant

Simon Authier, DVM, PhD, MBA, MSc, DSP

Charlene F. Barroga, PhD, DABT
VP/Head, Non-Clinical Drug Safety
Enveda Therapeutics Inc.

Brix Gil Bayuga, RPh
Director, Global Regulatory Affairs CMC and Devices
Eli Lilly and Company

Nicole Beard, PhD, MSc
Founder and Head of Regulatory Affairs
Biogecho Consulting Sarl

Jennifer G. Brown, PhD, RAC-US
Senior Director, Toxicology
MacroGenics, Inc.

Timothy A. Candy, PharmD, MS, BCPS
Principal Consultant, Regulatory Affairs
Opus Regulatory, LLC

Monique J. Carter, MS, FRAPS
Senior Director, Global Regulatory Strategy
Pfizer Inc.

Ricki A. Chase, MS
President
RChase Consulting, LLC

Rowena Cook, MS, RAC-Global, RCC-IVDR
Sr. Regulatory Affairs Specialist
Twist Bioscience

Angela W. Corona, PhD
Senior Scientific Director
Omnicom Health Medical Communications

Cristina Damatarca, MD, PGD
President
SafePharm LLC

Dhanraj Deshmukh, PhD, DABT
Senior Advisor - Toxicology
Eli Lilly and Company

Pragnesh Donga, MPharm, MBA, RAC-Drugs
Founder and CEO
ArKri Therapeutics

Jennifer Duru, PharmD
Regional Regulatory Stratist
Pfizer Inc.

Sue Duvall, MPA, RN, BS
Principal
Duvall Limited LLC

Robert Falcone, PhD, FTOPRA, FRAPS
Global Regulatory Manager
IDT – Danaher

Margaret L. Fleming, PhD
Senior Environmental Scientist
Personal Care Products Council

Cansin Gevrek, BS
Senior Regulatory Affairs Professional
Novo Nordisk A/S

Kathleen Grim, MS
Principal Consultant
Opus Regulatory, LLC

Alan M. Hoberman, PhD, DABT, ATSF
Senior Advisor
Charles River Laboratories

Karl-Heinz Huemer, MD, PhD
Founder
khh consult gmbh

Hannah Jin, BSc
Associate Director, CMC Regulatory Affairs - Devices & Digital Therapeutics
AstraZeneca

Nidhi Kotecha, PhD, MPharm, RAC-Drugs
Regulatory Affairs Program Director
Gates Institute, University of Colorado, Anschutz Medical Campus

Rebecca Lalani, PharmD
Principal Consultant
Opus Regulatory, LLC

Charles E. Lambert, PhD, DABT, ERT
Principal
Intrinsic

Yingying Liu, MSc
Associate Director
CSL

Danini Y. Marin, MSc
Regulatory Affairs Consultant

Jewell D. Martin, MBA, MA, PMP, RAC-US
Director of US R&D and Regulatory Policy
BioMarin Pharmaceutical Inc.

Karin McIntosh, MPharm, RAC-Drugs
Head of Regulatory Affairs
Orca Bio

Ben McLaughlin, MSE
Principal Consultant
Amylaza Consulting

Marcello Milano, MSc
Director, R&D and Regulatory Policy
BioMarin UK Ltd

Katelyn Jean Mulligan, EMBA, MS
Associate Director, Regulatory Affairs
Nefro Avillion Clinical Development

Kingman Ng, PhD
Executive Director
Eli Lilly and Company

Cathleen A. O'Connell, PhD, MS, RPh
Retired Regulatory Executive and
Associate Professor

Komalkumar Patel, MS
Associate Director, Pharmaceutical
Development
Experic LLC

Ajay Babu Pazhayattil, DBA, MPharm, CPGP
President
cGMP World

Kalaiselvan Ponnusamy, MVSc, DIBTP, DICVP, DABT
Assistant Director
Syngene International Limited

Zaida Recinos-Vasquez, MS, MS
Senior Manager, Regulatory Global
CMC Strategist
Pfizer Inc.

Brian M. Roche, PhD, DSP, DABT
General Manager
Charles River Laboratories

Darlene (Dar) Rosario, MBA, BS, RAC-US
Principal Consultant, Regulatory Affairs
CMC and Combination Products
Velocity Consulting

Barbara A. Rusin, MS
Owner/ Independent GxP Consultant
Phoenix Select Regulatory Consulting,
LLC

Leonor Saldanha, PhD, MS
Regulatory Affairs Manager
ThermoFisher Scientific

Brante P. Sampey, PhD, DABT
Director, Toxicology
Intrinsic

Jennifer K. Saxe, PhD, MBA
Global Lead, Environmental
Sustainability and Safety
Kenvue

Kathrin Schalper, PhD, RAC-Devices, RAC-US, RAC-CAN, RAC-EU
Principal Consultant, Regulatory Affairs
Senita Consulting, LLC

Neel Kamal Sharma, PhD, MS
Sr. Toxicologist
MacroGenics, Inc.

Salah Shawky, DrBA
Biologicals registration unit manager
Egyptian Drug Authority

Beat U. Steffen, MSc, MBA, RAC-Devices, FRAPS
Founder & Principal Consultant
confinis ag

Consuela Stewart
Owner and Principal Consultant
Kezoshi Regulatory Consulting

Ramesh Subramani, DVM, DABT, ERT, DSP, RAC-US
Preclinical Consultant

Jesshanie Tabaniag
Regulatory Program Management
Professional- International
Roche Products Limited

Sagar Thakali, PhD, IBERA
Environmental Steward
Kenvue

Pallavi Trivedi, MPH
Associate Director, Regulatory Affairs
Novo Nordisk A/S

Stephanie Turri Lockman, MS
Associate Director, Global Labeling
Product Leader
Johnson & Johnson

Rudradutt Singh Vaghela, PhD, RAC-Drugs
Senior Regulatory Affairs Professional
Novo Nordisk A/S

Tyler Vandivort, PhD, DABT, RAC-Drugs
Associate Director, Regulatory Affairs
Lead
UCB Pharma

Nikolaos Zacharias, MS
Regulatory Affairs Team Leader

Yuwei Zhang, MD, PhD, MPH, MBA
Director, Innovation & Digital Health
Northern Medical Center

Section Editors

This edition builds on the work of the section editors, whose contributions in the prior edition are deeply appreciated: Kimberly Belsky, MS, FRAPS; Devanshi Maharaja, MSc, MTech; Daniel G. Mannix, PhD, FRAPS; Flora Siami, MPH; Kip Vought.

Table of Contents

Section I: General Information

Chapter 1: The Drug Development Continuum, Preclinical to Market Access	3
Darlene (Dar) Rosario, MBA, BS, RAC-US; Pragnesh Donga, MPharm, MBA, RAC-Drugs; Kathrin Schalper, PhD, RAC-Devices, RAC-US, RAC-CAN, RAC-EU	
Chapter 2: International Harmonization via ICH, WHO, and Other Global Initiatives.....	19
Linda McBride, RPh, RAC-US	

Section II: Nonclinical Studies

Chapter 3: Principles of Good Laboratory Practice and Nonclinical Development.....	27
Neel Kamal Sharma, PhD, MS; Jennifer G. Brown, PhD, RAC-US	
Chapter 4: Safety Pharmacology Studies.....	37
Charlene F. Barroga PhD, DABT; Brian M. Roche, PhD, DSP, DABT; Simon Authier, DVM, PhD, MBA, MSc, DSP	
Chapter 5: Pharmacokinetic and Toxicokinetic Studies.....	53
Tyler Vandivort, PhD, DABT, RAC-Drugs; Dhanraj Deshmukh, PhD, DABT	
Chapter 6: Acute and Chronic Toxicity Assessments	65
Charles Lambert, PhD, DABT, ERT; Brante P. Sampey, PhD, DABT	
Chapter 7: Local Tolerance Studies	77
Ramesh Subramani, DVM, DABT, ERT, DSP, RAC-US	
Chapter 8: Genotoxicity Studies.....	83
Tyler Vandivort, PhD, DABT, RAC-Drugs; Ramesh Subramani, DVM, DABT, ERT, DSP, RAC-US	
Chapter 9: Carcinogenicity Studies	95
Tyler Vandivort, PhD, DABT, RAC-Drugs; Kalaiselvan Ponnusamy, MVSc, DIBTP, DICVP, DABT	
Chapter 10: Developmental and Reproductive Toxicity Assessments.....	107
Charlene F. Barroga, PhD, DABT; Alan M. Hoberman, PhD, DABT, ATSF	
Chapter 11: Regulatory Environmental Risk Assessment of Human Pharmaceuticals.....	121
Margaret L. Fleming, PhD; Sagar Thakali, PhD, IBERA; Jennifer K. Saxe, PhD, MBA	

Section III: Chemistry, Manufacturing, and Controls

Chapter 12: The Global Regulatory Process for the Registration of Active Substances	137
Darlene (Dar) Rosario, MBA, BS, RAC-US; Yuwei Zhang, MD, PhD, MPH, MBA; Robert Falcone, PhD, FTOPRA, FRAPS	